Appendix: Key Information on Newly Approved AML Drugs

Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C

Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas

Dr. Nix has served on the speakers bureau for Coherus BioSciences and advisory boards for Bristol-Myers Squibb, Genentech, Puma, Sandoz, and Teva. Ms. Price has served as a consultant for Agios and on an advisory board for Daiichi Sankyo.

Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail:

J Adv Pract Oncol 2019;10(suppl 4):23–29 | | © 2019 Harborside™



This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners

Table of Contents

  1. Acute Myeloid Leukemia: An Ever-Changing Disease
  2. Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
  3. The Role of the Advanced Practitioner in Enhancing Outcomes
  4. Appendix: Key Information on Newly Approved AML Drugs (current article)

For access to the full length article, please sign in.

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.